Invivyd stock falls after pricing capital raise of $50M via securities offering

Invivyd (NASDAQ:IVVD [https://seekingalpha.com/symbol/IVVD]) has priced a public offering [https://seekingalpha.com/pr/20207419-invivyd-announces-pricing-of-50-million-public-offering-of-common-stock-and-pre-funded] to raise approximately $50 million in gross proceeds via issuance of 74.81M shares of its common stock and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 21.34M shares of its common stock.

The company is selling a combination of common stock at $0.52 per share and pre-funded warrants at $0.5199 per warrant.

The underwriters also have a 30-day option to purchase up to an additional 14.42 million shares.

The company plans to use the money raised from the offering, along with its current cash, to fund its clinical programs. The funds will support the VYD2311 clinical program, research and development for new pipeline programs like those for RSV and measles, and efforts to study monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The company will also use the funds for working capital and other general corporate needs.

The offering is expected to close around August 22, 2025.

IVVD stock price were down 13.95% on Thursday during premarket.

MORE ON INVIVYD

* Invivyd announces proposed public offering of common stock [https://seekingalpha.com/news/4487659-invivyd-announces-proposed-public-offering-of-common-stock]
* Invivyd aligns with FDA on fast-track approval path for COVID-19 antibody VYD2311 [https://seekingalpha.com/news/4485867-invivyd-aligns-with-fda-on-fast-track-approval-path-for-covid-19-antibody-vyd2311]
* Seeking Alpha’s Quant Rating on Invivyd [https://seekingalpha.com/symbol/IVVD/ratings/quant-ratings]
* Historical earnings data for Invivyd [https://seekingalpha.com/symbol/IVVD/earnings]
* Financial information for Invivyd [https://seekingalpha.com/symbol/IVVD/income-statement]